Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CBFB | Q13951 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CCR1 | P32246 | 1/20 | 0.41 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
| ▸ | CCR8 | P51685 | 1/20 | 0.41 |
| ▸ | METAP1 | P53582 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14595530 | 0.85 | CBFB (0.51) | CBFBKDM4ENPC1CYP1A2CYP2D6 | |
| SCHEMBL21753236 | 0.84 | NPC1 (0.44) | KDM4ENPC1CYP1A2CYP2D6CYP19A1 | |
| SCHEMBL25455763 | 0.81 | NPC1 (0.47) | KDM4ENPC1CYP1A2CYP2D6CYP19A1 | |
| SCHEMBL12117401 | 0.81 | NPC1 (0.44) | KDM4ENPC1CYP1A2CYP2D6CYP19A1 | |
| SCHEMBL21769973 | 0.81 | CBFB (0.53) | CBFBKDM4ENPC1CYP1A2CYP2D6 | |
| SCHEMBL21753230 | 0.81 | KDM4E (0.47) | CBFBKDM4ECYP1A2CYP2D6CYP19A1 | |
| SCHEMBL25480188 | 0.81 | CYP2D6 (0.45) | CYP2D6CYP19A1CYP2C9CYP2C19DHODH | |
| SCHEMBL7662434 | 0.79 | KDM4E (0.56) | CBFBKDM4ENPC1CYP1A2CYP2D6 | |
| SCHEMBL172718 | 0.78 | HSD17B1 (0.51) | KDM4ENPC1CYP1A2RETRIPK1 | |
| SCHEMBL6224902 | 0.77 | CBFB (0.44) | CBFBKDM4ENPC1CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12016852-B2 | Pyrrolidine glycosidase inhibitors | ASCENEURON SA (CH) | 2024-06-25 | — | — | US | disclosed |
| US-12016852-B2 | Pyrrolidine glycosidase inhibitors | ASCENEURON SA (CH) | 2024-06-25 | — | — | US | disclosed |
| US-20210213005-A1 | PYRROLIDINE GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2021-07-15 | — | — | US | disclosed |
| US-20210213005-A1 | PYRROLIDINE GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2021-07-15 | — | — | US | disclosed |
| WO-2020039027-A1 | PYRROLIDINE GLYCOSIDASE INHIBITORS | ASCENEURON S. A. (CH) | 2020-02-27 | — | — | WO | disclosed |
| WO-2020039027-A1 | PYRROLIDINE GLYCOSIDASE INHIBITORS | ASCENEURON S. A. (CH) | 2020-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12016852-B2 | Pyrrolidine glycosidase inhibitors | PREP, GAA, DNPEP | CBFB 2674/4885KDM4E 2209/4885NPC1 612/4885 |
| US-20210213005-A1 | PYRROLIDINE GLYCOSIDASE INHIBITORS | PREP, GAA, DNPEP | CBFB 2508/4885KDM4E 1934/4885NPC1 596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.